Core Viewpoint - The company TianKang (301263.SZ) has received a notice of acceptance for the drug registration application of Safinamide Mesylate Tablets from the National Medical Products Administration (NMPA) in China, indicating progress in its product development for treating Parkinson's disease [1] Group 1: Company Developments - TianKang's wholly-owned subsidiary, Anhui TianKang Pharmaceutical Co., Ltd., has recently received the acceptance notice for the drug registration application [1] - The drug, Safinamide Mesylate Tablets, is a selective MAO-B inhibitor intended for the treatment of adult patients with idiopathic Parkinson's disease [1] - The drug is designed to be used as an adjunct therapy with stable doses of Levodopa, either alone or in combination with other Parkinson's disease treatments, particularly for patients experiencing mid to late-stage fluctuations [1]
泰恩康：甲磺酸沙非胺片收到药品注册受理通知书